OneSource Speci.
Biotechnology · ONESOURCE
Mid CapHealthcareHigh Growth
Neeraj Sharma
Chief Executive Officer and Managing Director · Pragmatic
Company DNA
Innovation-Led
About
OneSource Speci. is a Mid Cap company in the Healthcare sector, listed on NSE as ONESOURCE. With a market cap of ₹17K Cr and revenue of ₹1K Cr, it is currently in the High Growth phase. Known for its Innovation-Led culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Focuses on high-end niche manufacturing and R&D-linked biotech services requiring agile, product-centric mindsets. Its strategic mandate: As a specialized player, it must scale R&D capabilities to capture niche global pharma market demand.
FAQ
What kind of company is OneSource Speci.?
OneSource Speci. is a Mid Cap Healthcare company (ONESOURCE) in the High Growth phase with a market cap of ₹17K Cr. It is classified as Innovation-Led in culture.
What is OneSource Speci.'s culture and work environment like?
OneSource Speci. has a Innovation-Led culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Focuses on high-end niche manufacturing and R&D-linked biotech services requiring agile, product-centric mindsets.
Who leads OneSource Speci.?
OneSource Speci. is led by Neeraj Sharma (Chief Executive Officer and Managing Director), a Pragmatic leader with 30 years of experience.
What are OneSource Speci.'s financials?
OneSource Speci. reported revenue of ₹1K Cr in FY25 with a 5-year revenue CAGR of —. Operating margin: 13.2%. Market cap: ₹17K Cr.
Culture & Strategy
CultureInnovation-Led
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTechnical-Expert
LifecycleHigh Growth
Focuses on high-end niche manufacturing and R&D-linked biotech services requiring agile, product-centric mindsets.
Mandate
As a specialized player, it must scale R&D capabilities to capture niche global pharma market demand.
As a specialized player, it must scale R&D capabilities to capture niche global pharma market demand.
Financials
Revenue FY25₹1K Cr
PAT FY25₹-179710000
Rev CAGR 5Y—
OPM13.2%
NPM-1.2%
ROE-0.3%
ROCE3%
P/E833.1
Fwd P/E39.1
P/B2.9
D/E21.9
Mkt Cap₹17K Cr
Promoter39.9%
Institutional28.5%
Similar Culture
.png)
Could You Lead OneSource Speci.?
Take the Genome Benchmark →